Show simple item record

dc.contributor.authorWhitehead, I
dc.contributor.authorIrwin, GW
dc.contributor.authorBannon, F
dc.contributor.authorColes, Charlotte
dc.contributor.authorCopson, E
dc.contributor.authorCutress, RI
dc.contributor.authorDave, RV
dc.contributor.authorGardiner, MD
dc.contributor.authorGrayson, M
dc.contributor.authorHolcombe, C
dc.contributor.authorIrshad, S
dc.contributor.authorO'Brien, C
dc.contributor.authorO'Connell, RL
dc.contributor.authorPalmieri, C
dc.contributor.authorShaaban, AM
dc.contributor.authorSharma, N
dc.contributor.authorSingh, JK
dc.contributor.authorPotter, S
dc.contributor.authorMcIntosh, SA
dc.contributor.authorNeST Study Research Collaborative
dc.date.accessioned2021-02-02T00:31:58Z
dc.date.available2021-02-02T00:31:58Z
dc.date.issued2021-01-22
dc.identifier.issn1471-2407
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/316987
dc.description.abstractBACKGROUND: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast units, in terms of indications for use, radiological monitoring, pathological reporting of treatment response, and post-treatment surgical management. METHODS: Multidisciplinary teams (MDTs) from all UK breast units were invited to participate in the NeST study. A detailed questionnaire assessing current stated practice was distributed to all participating units in December 2017 and data collated securely usingREDCap. Descriptive statistics were calculated for each questionnaire item. RESULTS: Thirty-nine MDTs from a diverse range of hospitals responded. All MDTs routinely offered neoadjuvant chemotherapy (NACT) to a median of 10% (range 5-60%) of patients. Neoadjuvant endocrine therapy (NET) was offered to a median of 4% (range 0-25%) of patients by 66% of MDTs. The principal indication given for use of neoadjuvant therapy was for surgical downstaging. There was no consensus on methods of radiological monitoring of response, and a wide variety of pathological reporting systems were used to assess tumour response. Twenty-five percent of centres reported resecting the original tumour footprint, irrespective of clinical/radiological response. Radiologically negative axillae at diagnosis routinely had post-NACT or post-NET sentinel lymph node biopsy (SLNB) in 73.0 and 84% of centres respectively, whereas 16% performed SLNB pre-NACT. Positive axillae at diagnosis would receive axillary node clearance at 60% of centres, regardless of response to NACT. DISCUSSION: There is wide variation in the stated use of neoadjuvant systemic therapy across the UK, with general low usage of NET. Surgical downstaging remains the most common indication of the use of NAC, although not all centres leverage the benefits of NAC for de-escalating surgery to the breast and/or axilla. There is a need for agreed multidisciplinary guidance for optimising selection and management of patients for NST. These findings will be corroborated in phase II of the NeST study which is a national collaborative prospective audit of NST utilisation and clinical outcomes.
dc.format.mediumElectronic
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectNeST Study Research Collaborative
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectPrognosis
dc.subjectNeoadjuvant Therapy
dc.subjectInterdisciplinary Communication
dc.subjectDecision Making
dc.subjectFemale
dc.subjectSurveys and Questionnaires
dc.subjectUnited Kingdom
dc.titleThe NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
dc.typeArticle
prism.issueIdentifier1
prism.publicationDate2021
prism.publicationNameBMC Cancer
prism.startingPage90
prism.volume21
dc.identifier.doi10.17863/CAM.64099
dcterms.dateAccepted2020-12-21
rioxxterms.versionofrecord10.1186/s12885-020-07757-6
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-01-22
dc.contributor.orcidColes, Charlotte [0000-0003-4473-8552]
dc.identifier.eissn1471-2407
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-01-22


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International